Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy.
He C, Duan X, Guo N, Chan C, Poon C, Weichselbaum RR, Lin W. · 2016
Read Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. by He C, Duan X, Guo N, Chan C, Poon C, Weichselbaum RR, Lin W. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4992065.txt.
Introduction
Chunbai He and six co-authors build nanoparticles that combine chemotherapy, light therapy, and immune checkpoint blockade against colon cancer. Their study appeared in Nature Communications in 2016. Metastatic colorectal cancer has a five year survival rate of only twelve percent, and checkpoint drugs alone help few patients. The team's core-shell particles carry the chemo drug oxaliplatin in the core and a light activated compound in the shell.
Light triggers the shell compound to kill tumor cells while the chemo drug acts inside. The joint killing exposes calreticulin on cell surfaces, a signal that recruits immune attack and works like a vaccine. Adding an anti-PD-L1 antibody then shrank both irradiated tumors and distant untreated ones in mice. The authors argue the pairing turns a local treatment into a body wide immune response.
Catalog record
| CREATOR | He C, Duan X, Guo N, Chan C, Poon C, Weichselbaum RR, Lin W. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy By Chunbai He, Xiaopin Duan, Nining Guo, Christina Chan, Christopher Poon, Ralph R. Weichselbaum, Wenbin Lin Published in: Nature Communications DOI: 10.1038/ncomms12499 ABSTRACT Advanced colorectal cancer is one of the deadliest cancers, with a 5-year survival rate of only 12% for patients with the metastatic disease. Checkpoint inhibitors, such as the antibodies inhibiting the PD-1/PD-L1 axis, are among the most promising immunotherapies for patients with advanced colon cancer, but their durable response rate remains low. We herein report the use of immunogenic nanoparticles to augment the antitumour efficacy of PD-L1 antibody-mediated cancer immunotherapy. Nanoscale coordination polymer (NCP) core-shell nanoparticles carry oxaliplatin in the core and the photosensitizer pyropheophorbide-lipid conjugate (pyrolipid) in the shell (NCP@pyrolipid) for effective chemotherapy and photodynamic therapy (PDT). Synergy between oxaliplatin and pyrolipid-induced PDT kills tumour cells and provokes an immune response, resulting in calreticulin exposure on the cell surface, antitumour vaccination and an abscopal effect. When combined with anti-PD-L1 therapy, NCP@pyrolipid mediates regression of both light-irradiated primary tumours and non-irradiated distant tumours by inducing a strong tumour-specific immune response. Approximately 150,000 patients are diagnosed with colorectal cancer in the United States annually, with one-third dying from metastasis1. Although the 5-year survival rate for localized colorectal cancer is ∼89%, this number drops to only ∼12% for cancers that have metastasized to the liver, lungs or peritoneum2. Stimulation of the host immune system has been shown to generate an antitumour immune response capable of controlling metastatic tumour growth3456. Immune checkpoint blockade therapy, which targets regulatory pathways in T cells to enhance antitumour immune response, has witnessed significant clinical advances and provided a new strategy to combat cancer7. Among them, the PD-1/PD-L1 pathway inhibits immune activation by suppressing effector T-cell function89 and is upregulated in many tumours to cause apoptosis of tumour-specific cytotoxic T-lymphocytes and transmit an anti-apoptotic signal to tumour cells1011. Antibody-mediated specific blockade of the PD-1/PD-L1 axis can generate potent antitumour activity in murine tumour models1213. With the exception of metastatic melanoma, the durable responses generated by checkpoint blockade therapy are still low. Although blockade of PD-1 was shown not to be effective in metastatic colon cancer, a recent report by Le et al.14 demonstrated that PD-1 blockade was effective in a subset of colon cancer patients who were deficient in mismatch repair, reopening the door to immune modulation with interventions such as chemotherapy and radiotherapy to increase the durable response rate15. We hypothesize that combining PD-L1 blockade with multimodality nanoscale coordination polymer (NCP) nanoparticles can increase the response rate of checkpoint blockade cancer immunotherapy and perhaps broaden the use of immunotherapy in metastatic colon cancer. As a new class of self-assembled hybrid nanomaterials composed of metal connecting points and organic bridging ligands1617, NCPs have highly tunable compositions and structures, can combine multiple therapeutic agents or modalities18 and are intrinsically biodegradable. By combining non-toxic photosensitizers, light and oxygen to produce cytotoxic reactive oxygen species, in particular singlet oxygen (1O2), photodynamic therapy (PDT) kills cancer cells by apoptosis and necrosis, stimulates the host immune system and causes acute inflammation and leukocyte infiltration to the tumours, which increases the presentation of tumour-derived antigens to T cells19202122232425. Oxaliplatin was shown to induce immunogenic cell death (ICD) in murine colorectal cancer models26. We herein report the design of NCP nanoparticles that carry oxaliplatin and the photosensitizer pyrolipid (NCP@pyrolipid), to significantly enhance antitumour immunity. NCP@pyrolipid combines two therapeutic modalities, chemotherapy and PDT, to elicit antitumour immunity272829, as evidenced by early calreticulin (CRT) exposure on the cell surface, antitumour vaccination, tumour-specific T-cell response and an abscopal effect. The abscopal effect is usually described with ionizing radiation and refers to regression of tumour outside of the irradiated volume. Although the mechanism is unknown, it is thought to be immune modulated. More importantly, NCP@pyrolipid PDT treatment in combination with PD-L1 checkpoint blockade therapy not only led to the regression of the primary tumours, treated locally with light irradiation, but also resulted in the regression of the distant tumours in bilateral syngeneic mouse tumour models of CT26 and MC38 by generating systemic tumour-specific T-cell response with the infiltration of CD8+ T cells and CD4+ T cells in distant tumours. RESULTS Self-assembly and characterization of NCP@pyrolipid Fig. 1 illustrates our overall treatment strategy with multimodality NCP@pyrolipid nanoparticles. NCP@pyrolipid is a core-shell nanostructure with NCP carrying oxaliplatin as its solid core and a self-assembled asymmetric lipid bilayer as its shell (Fig. 2a). The NCP cores were constructed from the coordination polymerization between Zn2+ and phosphate groups of the oxaliplatin prodrug, which were further capped with a monolayer of 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA) via Zn–phosphate interactions between NCPs and DOPA molecules, and hydrophobic–hydrophobic interactions among DOPA molecules16. Pyrolipid, a lipid conjugate of pyropheophorbide-a, was synthesized via esterification between 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine and pyropheophorbide-a, and incorporated into the outer lipid layer via hydrophobic/hydrophobic interactions. The lipid shell also contains 20 mol% of polyethylene glycol to minimize mononuclear phagocyte system (MPS) uptake and prolong blood circulation after systemic injection. The spherical DOPA-coated NCP particles possess a Z-average diameter of 55.3±0.2 nm, as determined by dynamic light scattering (DLS; Fig. 2c), and an oxaliplatin loading of 27.6 wt%, as determined by inductively coupled plasma-mass spectrometry (ICP-MS). Transmission electron microscopy image of NCP@pyrolipid demonstrated the formation of uniformly spherical nanoparticles (Fig. 2b). DLS measurements gave a Z-average diameter, number-average diameter, polydispersity index and zeta potential of 83.0±1.0, 51.2±0.1 nm, 0.14±0.01 and −3.7±0.9 mV, respectively (Fig. 2c and Supplementary Fig. 1), of NCP@pyrolipid dispersed in phosphate-buffered saline (PBS). With intact lipid bilayer structures, the pyrolipid excited states of NCP@pyrolipid are highly quenched, thereby preventing energy transfer to triplet oxygen, as evidenced by the low amount of 1O2 detected by the singlet oxygen sensor green reagent (Supplementary Figs 2 and 3, and Supplementary Methods). After adding Triton X-100 to NCP@pyrolipid and porphysome (as a control particle)30313233 to disrupt the lipid bilayer, pyrolipid regained its fluorescence and the released species from both systems efficiently generated similar amounts of 1O2 upon photoexcitation. The release profiles of oxaliplatin from DOPA-NCP and NCP@pyrolipid were studied in PBS. DOPA-NCP exhibited rapid burst release, with 76% cumulative release of oxaliplatin within 2 h. In contrast, the release of oxaliplatin from NCP@pyrolipid was slow and sustained, with only 5.6% and 21% oxaliplatin released within 2 and 96 h, respectively (Supplementary Fig. 4), suggesting that the lipid bilayer can effectively prevent premature drug release during particle circulation in the blood. Investigation of ICD CRT is a distinct biomarker exposed on the surface of cells undergoing ICD3435. We first evaluated time-dependent cellular uptake of NCP@pyrolipid from 1 to 24 h in CT26 cells (Supplementary Fig. 5). After the demonstration of efficient cellular uptake and negligible efflux of NCP@pyrolipid in CT26 cells, the CRT expression on cells treated with NCP@pyrolipid was determined by flow cytometry (Fig. 3a) and immunofluorescence (Supplementary Fig. 6) and compared with PBS-, oxaliplatin-, NCP- and porphysome-treated cells. We collected and stained cells with Alexa Fluor 488-CRT antibody and propidium iodide (PI) for flow cytometry analysis, where the fluorescence intensity of CRT-stained cells was gated on PI-negative cells. For immunostaining analysis, the cells were stained with Alexa Fluor 488-CRT and 4,6-diamidino-2-phenylindole (DAPI) and observed under confocal laser scanning microscopy (CLSM). Significant